PL3724336T3 - Ulepszony związek do leczenia niewydolności serca - Google Patents

Ulepszony związek do leczenia niewydolności serca

Info

Publication number
PL3724336T3
PL3724336T3 PL18833849.5T PL18833849T PL3724336T3 PL 3724336 T3 PL3724336 T3 PL 3724336T3 PL 18833849 T PL18833849 T PL 18833849T PL 3724336 T3 PL3724336 T3 PL 3724336T3
Authority
PL
Poland
Prior art keywords
treatment
heart failure
improved compound
compound
improved
Prior art date
Application number
PL18833849.5T
Other languages
English (en)
Inventor
Thomas Thum
Sandor BATKAI
Ariana FOINQUINOS
Original Assignee
Medizinische Hochschule Hannover
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Hochschule Hannover filed Critical Medizinische Hochschule Hannover
Publication of PL3724336T3 publication Critical patent/PL3724336T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL18833849.5T 2017-12-15 2018-12-14 Ulepszony związek do leczenia niewydolności serca PL3724336T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762599050P 2017-12-15 2017-12-15
EP17207738 2017-12-15
PCT/EP2018/085008 WO2019115788A1 (en) 2017-12-15 2018-12-14 Improved compound for treatment of heart failure

Publications (1)

Publication Number Publication Date
PL3724336T3 true PL3724336T3 (pl) 2022-08-08

Family

ID=65023844

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18833849.5T PL3724336T3 (pl) 2017-12-15 2018-12-14 Ulepszony związek do leczenia niewydolności serca

Country Status (20)

Country Link
US (2) US11208651B2 (pl)
EP (1) EP3724336B1 (pl)
JP (1) JP7253834B2 (pl)
KR (1) KR20200104294A (pl)
CN (1) CN111630168B (pl)
AU (1) AU2018383013A1 (pl)
BR (1) BR112020009532A2 (pl)
CA (1) CA3084111A1 (pl)
CL (1) CL2020001578A1 (pl)
DK (1) DK3724336T3 (pl)
ES (1) ES2910303T3 (pl)
HU (1) HUE058867T2 (pl)
IL (1) IL275273B1 (pl)
MX (1) MX2020006198A (pl)
PH (1) PH12020550589A1 (pl)
PL (1) PL3724336T3 (pl)
RS (1) RS63078B1 (pl)
SI (1) SI3724336T1 (pl)
WO (1) WO2019115788A1 (pl)
ZA (1) ZA202002529B (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114450067B (zh) * 2019-06-14 2024-03-15 卡迪奥尔药物有限公司 人受试者的心力衰竭的治疗

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
EP1791954A1 (en) * 2004-09-07 2007-06-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial
US20070065840A1 (en) * 2005-03-23 2007-03-22 Irena Naguibneva Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS
EP3002330A1 (en) * 2005-05-27 2016-04-06 Ospedale San Raffaele S.r.l. Gene vector
US8748101B2 (en) * 2008-11-10 2014-06-10 Battelle Memorial Institute Methods, compositions, and devices utilizing MicroRNA to determine physiological conditions
WO2010105096A2 (en) * 2009-03-11 2010-09-16 University Of Massachusetts Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212)
US20120107825A1 (en) * 2010-11-01 2012-05-03 Winger Edward E Methods and compositions for assessing patients with reproductive failure using immune cell-derived microrna
EP2474617A1 (en) * 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
US9388411B2 (en) * 2011-09-06 2016-07-12 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. miRNA-212/132 family as a therapeutic target
CN103361428B (zh) * 2013-06-21 2016-06-22 徐州医学院 miRNA-132化合物在制备慢性疼痛诊断标志物及治疗药物中的应用
US10174320B2 (en) * 2014-09-21 2019-01-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Downregulating miR-132 for the treatment of lipid related disorders
CN114450067B (zh) * 2019-06-14 2024-03-15 卡迪奥尔药物有限公司 人受试者的心力衰竭的治疗
US20230265426A1 (en) * 2020-07-23 2023-08-24 Johann Wolfgang Goethe-Universität Frankfurt Combinatorial inhibition of mirnas for treatment of heart failure
CN112043721B (zh) * 2020-09-04 2022-01-28 南通大学 miR-132-5p在制备神经再生药物或材料中的应用
CN115068632A (zh) * 2022-06-22 2022-09-20 华中科技大学同济医学院附属同济医院 Ago2在制备治疗心衰的药物方面的用途及其蛋白、基因、转化体、药物与制备方法

Also Published As

Publication number Publication date
MX2020006198A (es) 2020-11-24
AU2018383013A1 (en) 2020-06-11
US20210180054A1 (en) 2021-06-17
EP3724336A1 (en) 2020-10-21
HUE058867T2 (hu) 2022-09-28
JP2021506268A (ja) 2021-02-22
ZA202002529B (en) 2021-08-25
JP7253834B2 (ja) 2023-04-07
US11208651B2 (en) 2021-12-28
RU2020122587A (ru) 2022-01-10
PH12020550589A1 (en) 2021-04-26
BR112020009532A2 (pt) 2020-11-03
CN111630168A (zh) 2020-09-04
EP3724336B1 (en) 2022-02-09
IL275273A (en) 2020-07-30
WO2019115788A1 (en) 2019-06-20
RU2020122587A3 (pl) 2022-01-10
US20220162597A1 (en) 2022-05-26
DK3724336T3 (da) 2022-03-21
CA3084111A1 (en) 2019-06-20
CL2020001578A1 (es) 2020-11-06
RS63078B1 (sr) 2022-04-29
ES2910303T3 (es) 2022-05-12
KR20200104294A (ko) 2020-09-03
IL275273B1 (en) 2024-05-01
SI3724336T1 (sl) 2022-05-31
CN111630168B (zh) 2023-09-22

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
EP3261713A4 (en) Blood pump for treatment of bradycardia
GB201804514D0 (en) Treatment of pyroptosis
HK1258128A1 (zh) 選擇病人接受組合療程
EP3169259A4 (en) Cardiac cryolipolysis for the treatment of cardiac arrhythmia
IL259297A (en) Heterocyclic compounds for the treatment of disease
EP3256137A4 (en) Method of treating heart failure
GB201804515D0 (en) Treatment of necroptosis
IL250662A0 (en) Tissue protection devices for the treatment of heart failure and other conditions
SG11201704781XA (en) Prevention of progressive heart failure
GB2564801B (en) Implantable scaffolds for treatment of sinusitis
EP3259346A4 (en) P63 inactivation for the treatment of heart failure
IL275273A (en) An improved compound for the treatment of heart failure
EP3481399A4 (en) METHOD FOR TREATING HEART INSUFFICIENCY
EP3601565A4 (en) MIR-92 INHIBITORS IN THE TREATMENT OF HEART FAILURE
HK1246679A1 (zh) 絲蟲病的治療
EP3612178A4 (en) VASODILATERS FOR THE TREATMENT OF HEART FAILURE
GB201907305D0 (en) Treatment of conditions
PT3724336T (pt) Composto melhorado para tratamento de insuficiência cardíaca
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
EP3503965B8 (en) Treatment of cardiac dysfunction
IL280243A (en) Compounds similar to 17beta-heterocyclyl-digitalis for the treatment of heart failure
GB201917253D0 (en) Treatment of conditions
GB201706608D0 (en) Acoustic means for treatment of heart arrhythmia
GB201801249D0 (en) Methods of treatment